Syracuse Biopharma (Cayman) II, Ltd. - Net Worth and Insider Trading

Syracuse Biopharma (Cayman) II, Ltd. Net Worth

The estimated net worth of Syracuse Biopharma (Cayman) II, Ltd. is at least $63 Million dollars as of 2024-09-13. Syracuse Biopharma (Cayman) II, Ltd. is the 2501 Other of JW (Cayman) Therapeutics Co Ltd and owns about 48,513,377 shares of JW (Cayman) Therapeutics Co Ltd (HKSE:02126) stock worth over $63 Million. Details can be seen in Syracuse Biopharma (Cayman) II, Ltd.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Syracuse Biopharma (Cayman) II, Ltd. has not made any transactions after 2021-08-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Syracuse Biopharma (Cayman) II, Ltd.

Syracuse Biopharma (Cayman) II, Ltd. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Syracuse Biopharma (Cayman) II, Ltd. owns 1 companies in total, including JW (Cayman) Therapeutics Co Ltd (HKSE:02126) .

Click here to see the complete history of Syracuse Biopharma (Cayman) II, Ltd.’s form 4 insider trades.

Insider Ownership Summary of Syracuse Biopharma (Cayman) II, Ltd.

Ticker	Comapny	Transaction Date	Type of Owner
HKSE:02126	JW (Cayman) Therapeutics Co Ltd	2021-08-27	2501 Other

Syracuse Biopharma (Cayman) II, Ltd. Latest Holdings Summary

Syracuse Biopharma (Cayman) II, Ltd. currently owns a total of 1 stock. Syracuse Biopharma (Cayman) II, Ltd. owns 48,513,377 shares of JW (Cayman) Therapeutics Co Ltd (HKSE:02126) as of August 27, 2021, with a value of $63 Million.

Latest Holdings of Syracuse Biopharma (Cayman) II, Ltd.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:02126	JW (Cayman) Therapeutics Co Ltd	2021-08-27	48,513,377	1.30	63,067,390

Holding Weightings of Syracuse Biopharma (Cayman) II, Ltd.

Syracuse Biopharma (Cayman) II, Ltd. Form 4 Trading Tracker

According to the SEC Form 4 filings, Syracuse Biopharma (Cayman) II, Ltd. has made a total of 1 transactions in JW (Cayman) Therapeutics Co Ltd (HKSE:02126) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in JW (Cayman) Therapeutics Co Ltd is the sale of 48,513,377 shares on August 27, 2021, which brought Syracuse Biopharma (Cayman) II, Ltd. around $0.

Insider Trading History of Syracuse Biopharma (Cayman) II, Ltd.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Syracuse Biopharma (Cayman) II, Ltd. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Syracuse Biopharma (Cayman) II, Ltd. Ownership Network

Ownership Network List of Syracuse Biopharma (Cayman) II, Ltd.

No Data

Ownership Network Relation of Syracuse Biopharma (Cayman) II, Ltd.

Syracuse Biopharma (Cayman) II, Ltd. Owned Company Details

What does JW (Cayman) Therapeutics Co Ltd do?

Who are the key executives at JW (Cayman) Therapeutics Co Ltd?

Syracuse Biopharma (Cayman) II, Ltd. is the 2501 Other of JW (Cayman) Therapeutics Co Ltd. Other key executives at JW (Cayman) Therapeutics Co Ltd include 2202 Interest of your spouse Li Dan , 2201 Interest of corporation controlled by you Li Yiping James , and 2201 Interest of corporation controlled by you Bristol-myers Squibb Company .

JW (Cayman) Therapeutics Co Ltd (HKSE:02126) Insider Trades Summary

Over the past 18 months, Syracuse Biopharma (Cayman) II, Ltd. made no insider transaction in JW (Cayman) Therapeutics Co Ltd (HKSE:02126). Other recent insider transactions involving JW (Cayman) Therapeutics Co Ltd (HKSE:02126) include a net sale of 0 shares made by Li Yiping James , and a net sale of 0 shares made by Li Dan .

In summary, during the past 3 months, insiders sold 0 shares of JW (Cayman) Therapeutics Co Ltd (HKSE:02126) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of JW (Cayman) Therapeutics Co Ltd (HKSE:02126) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

JW (Cayman) Therapeutics Co Ltd (HKSE:02126)'s detailed insider trading history can be found in Insider Trading Tracker table.

JW (Cayman) Therapeutics Co Ltd Insider Transactions

No Available Data

Syracuse Biopharma (Cayman) II, Ltd. Mailing Address

Above is the net worth, insider trading, and ownership report for Syracuse Biopharma (Cayman) II, Ltd.. Currently GuruFocus does not have mailing address information for Syracuse Biopharma (Cayman) II, Ltd..

Discussions on Syracuse Biopharma (Cayman) II, Ltd.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.